Pratt studies the brain circuits behind food motivation and draws on decades of that work to explain what may change when GLP-1 drugs dial cravings down.
Recap by typeshit. Post by Facebook on Facebook.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
His weekly medicine roundup lists Lilly's triple agonist results next to the optogenetics Nobel and an ARPA-H plan to speed drug development.
That tops 14.8% on high-dose tirzepatide alone, though 27% dropped out over side effects. CNBC-TV18 says phase 3 is planned by end of 2026.
Loading…